The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...

The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...

Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual ...

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Gwen Nichols, MD, discussed the potential implications of recent funding cuts, how they are affecting academic and community ...

A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...

Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against ...

Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.